Skip to content
MarketScale
‹ Back to Industries

Sciences

James Webb Telescope Observations Heat up with Coldest Ice Detection

The harshest arctic winters have got nothing on the chill from deep space. The James Webb Space Telescope (JWST) continues to provide gifts for scientists and space enthusiasts with its latest discovery: ice found within the deepest reaches of an interstellar molecular cloud. As reported in the journal Nature Astronomy, the JWST measured the frozen…

This story was produced through MarketScale. See how Sciences teams put it to work with Executive Thought Leadership.

By Sciences · Interstellar StudiesJames Webb TelescopeJwstSpace Exploration
Share

Key takeaways

01

The harshest arctic winters have got nothing on the chill from deep space.

02

The James Webb Space Telescope (JWST) continues to provide gifts for scientists and space enthusiasts with its latest discovery: ice found within the deepest reaches of an interstellar molecular cloud.

03

As reported in the journal Nature Astronomy, the JWST measured the frozen…

The harshest arctic winters have got nothing on the chill from deep space. The James Webb Space Telescope (JWST) continues to provide gifts for scientists and space enthusiasts with its latest discovery: ice found within the deepest reaches of an interstellar molecular cloud. As reported in the journal Nature Astronomy, the JWST measured the frozen molecules at minus 440 degrees Fahrenheit (minus 263 degrees Celsius).

Could this discovery provide clues to early planet formation and possible early lifeforms?

“These observations open a new window on the formation pathways for the simple and complex molecules that are needed to make the building blocks of life,” lead study author Melissa McClure, an astronomer at Leiden Observatory in the Netherlands, said.

How is the rest of the scientific community responding to this life-altering (literally) news? Jason Steffen, Assistant Professor of Physics and Astronomy at the University of Nevada, Las Vegas, and member of NASA’s Kepler mission science team since 2008, gave some context around this latest JWST observation and why other astronomers and space professionals are eager to learn even more about these icy molecules.

In related efforts, the University of Nevada, Las Vegas research team discovered a new form of ice that redefines the properties of water at high pressures. This type of high-pressure water may be present in the interior of distant planets under immense strain from the forces of gravity. Perhaps this is the next bucket list item for the JWST to discover as it continues to probe the unknown reaches of space.

Jason’s Thoughts

“New results from the James Webspace Telescope Show it has the power to do exactly what it was designed to do. That is to peer through layers of cold gas and dust to see what is going on behind them. These layers would be opaque to visible light and hide the goings-on deep inside the coldest and dirtiest places in the universe.

In this study, astronomers use the James Webspace Telescope to study the composition of condensed material deep within the cold cloud of gas called Chameleon I. This is a cloud where stars are forming. They wanted to see how different ices or molecules of light elements condensed out of that cloud. These light elements include carbon, oxygen, nitrogen, hydrogen, and sulfur, and these elements are important for the formation of planets as well as the development of planetary atmospheres and eventually life on any of these planets that might form as infrared light from distant stars pass through that cloud.

It will be absorbed by these different ices, and we can measure what they’re made out of within that. These results will help us piece together the development of planet-forming material from within this cloud. And it’s especially important because this is before the time that most of the stars have formed and certainly before the time that any of the planets have formed.”

Article by James Kent.

About the author

S
Sciences

New to MarketScale?

MarketScale is the platform Sciences companies use to turn their own experts into content like this. Want the short overview?

Free workspace

You just read one expert. Imagine publishing your whole team.

This article was produced through MarketScale. Create a free workspace and turn your own team's expertise into articles, video, and social posts. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale Studio workspace
One video edit a month, on us
AI writing, editing, and publishing tools
In-platform coaching to learn the system

More Sciences Insights

Biopharma's $300 Billion Problem Is Driving the Biggest M&A Cycle in a Decade

Biopharma's $300 Billion Problem Is Driving the Biggest M&A Cycle in a Decade

The pharmaceutical industry is facing a significant challenge as over $300 billion in branded pharmaceutical revenue is set to lose patent protection by 2030. This revenue gap is driving the largest merger and acquisition cycle seen in a decade, with companies seeking external growth through acquisitions. This shift is impacting the entire life sciences supply chain, prompting strategic changes across the industry.

  • 01Over $300 billion in pharmaceutical revenue is at risk due to patent expirations by 2030.
  • 02Big Pharma is engaging in an aggressive cycle of mergers and acquisitions.
  • 03The acquisitions are reshaping the life sciences supply chain.

Jun 29, 2026

Quotient Sciences launches Phase I study of what it calls the first AI-formulated drug in the clinic

Quotient Sciences launches Phase I study of what it calls the first AI-formulated drug in the clinic

Quotient Sciences has initiated a Phase I clinical study at its UK facility for an oral solid dose formulation designed using artificial intelligence — what the company believes is the first AI-formulated drug to reach human clinical evaluation. The study, cleared by the UK's Medicines and Healthcare products Regulatory Agency, will assess safety and pharmacokinetics in healthy volunteers. The program, which used Intrepid Labs' machine learning algorithm, signals a broader shift in how contract drug development organizations are integrating AI across formulation and clinical workflows.

  • 01Quotient Sciences initiated a Phase I study of an AI-designed oral solid dose formulation at its UK facility following MHRA approval — the first such case the company believes has been reported.
  • 02The formulation was developed using Intrepid Labs' advanced machine learning algorithm in combination with Quotient Sciences' Translational Pharmaceutics platform.
  • 03The milestone is part of a broader CRDMO strategy to embed AI-enabled approaches across formulation development and clinical workflows, with implications for the wider contract pharma sector.

Jun 17, 2026

Quotient Sciences launches Phase I trial of what it calls the first AI-formulated drug to reach the clinic

Quotient Sciences launches Phase I trial of what it calls the first AI-formulated drug to reach the clinic

Quotient Sciences has initiated a Phase I clinical study of an oral solid dose formulation designed using AI, cleared by the UK's MHRA and conducted at the company's UK facility. The trial—built on machine learning algorithms from partner Intrepid Labs and Quotient's Translational Pharmaceutics platform—aims to validate AI as a direct contributor to formulation design rather than just an upstream analytical tool. Benchling characterizes the broader moment as biotech entering a "builder phase," in which leading organizations embed AI capability at the bench level rather than running isolated pilots.

  • 01Quotient Sciences has dosed healthy volunteers in a Phase I study it describes as the first clinical evaluation of an AI-designed oral formulation, following approval from the UK's MHRA.
  • 02The formulation was developed using advanced machine learning algorithms from Intrepid Labs, integrated with Quotient Sciences' Translational Pharmaceutics platform.
  • 03Benchling identifies a sector-wide shift toward embedding AI capability directly at the bench, moving beyond isolated pilots to structural adoption across biotech R&D.

Jun 17, 2026

Explore More Sciences Insights

Read more expert perspectives from across Sciences.

Browse Sciences Hub

About the Expert

S
Sciences